Alumis (ALMS) Revenue (2025)
Alumis (ALMS) reported Revenue of $1.9 million for Q4 2025, down 6.63% on a QoQ basis from $2.1 million in Q3 2025.
Alumis (ALMS) has 1 years of Revenue data on file, last reported at $1.9 million in Q4 2025.
- Quarterly Revenue changed N/A year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.0 million (changed N/A YoY) and the FY2025 annual result came in at $24.0 million, changed N/A from the prior year.
- Revenue slipped to $1.9 million in Q4 2025 per ALMS's latest filing, from $2.1 million in the prior quarter.
- Across five years, Revenue topped out at $17.4 million in Q1 2025 and bottomed at $1.9 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Alumis | 1.84 Bn | 1.75 Bn | - | 1.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.93 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.67 Mn |
| Mar 31, 2025 | 17.39 Mn |